The Leadership Core is a resource comprised of the individuals who will provide two essential components of the P01. The first is the central organizational, operational, and oversight coordination. The second is the planning, preparation, coordination, and performance of the statistical analyses, including the interpretation of molecular microarrays. The Leadership Core includes the Program Director, the Co-Program Director, the Coordinators of Molecular Array Technology and Inter-Project Integration, the Biostatistician, and Liaisons to the Departments of Medicine and Pathology. A major purpose of this core is to promote the integration of the five projects and the Imaging Core. It must be emphasized that the projects are being conducted in well-established, highly-productive laboratories that are led by some of the leaders in the field of cancer research and basic biological science. Hence, the prime form of cooperation/collaboration among the projects consists of the exchange of concepts, bio-constructs including transgenic mice, unique chemicals, imaging expertise, methods for the characterization of genotypes and phenotypes, and constructive deliberation concerning the design, conduct, and analysis of mouse studies. In an institution the size and breadth of MSKCC it cannot be assumed that interactions happen spontaneously, so it takes concerted effort?such as the P01?to make them happen. We have enjoyed considerable benefit in this regard from our monthly meetings and through the efforts of our bio-statistician (Dr. Olshen), but we intend to take the process a step further by the appointment of Dr. Mary Ellen Moynahan?an accomplished scientist (Project 4) and clinician?as Coordinator of Inter-Project Integration. Her specific activities are listed in the budget justification for this core and her qualifications are described below.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA094060-10
Application #
8382403
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
10
Fiscal Year
2012
Total Cost
$433,320
Indirect Cost
$204,775
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Chen, Chun-Chin; Kass, Elizabeth M; Yen, Wei-Feng et al. (2017) ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair. Proc Natl Acad Sci U S A 114:7665-7670
Ebbesen, Saya H; Scaltriti, Maurizio; Bialucha, Carl U et al. (2016) Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. Proc Natl Acad Sci U S A 113:3030-5
Malladi, Srinivas; Macalinao, Danilo G; Jin, Xin et al. (2016) Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell 165:45-60
Gao, Hua; Chakraborty, Goutam; Zhang, Zhanguo et al. (2016) Multi-organ Site Metastatic Reactivation Mediated by Non-canonical Discoidin Domain Receptor 1 Signaling. Cell 166:47-62
Rodrik-Outmezguine, Vanessa S; Okaniwa, Masanori; Yao, Zhan et al. (2016) Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature 534:272-6
Chen, Qing; Boire, Adrienne; Jin, Xin et al. (2016) Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature 533:493-498
Kass, Elizabeth M; Lim, Pei Xin; Helgadottir, Hildur R et al. (2016) Robust homology-directed repair within mouse mammary tissue is not specifically affected by Brca2 mutation. Nat Commun 7:13241
She, Qing-Bai; Gruvberger-Saal, Sofia K; Maurer, Matthew et al. (2016) Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer. BMC Cancer 16:587
Yang, C; Li, Z; Bhatt, T et al. (2016) Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene :
Jacob, Leni S; Vanharanta, Sakari; Obenauf, Anna C et al. (2015) Metastatic Competence Can Emerge with Selection of Preexisting Oncogenic Alleles without a Need of New Mutations. Cancer Res 75:3713-9

Showing the most recent 10 out of 96 publications